Buscar
Mostrando ítems 1-10 de 37
Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
(BENTHAM SCIENCE PUBL LTD, 2010)
Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand)complexes, including the drugs ...
Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation
(PERGAMON-ELSEVIER SCIENCE LTD, 2008)
[Ru-2(dNSAID)(4)Cl] and novel [Ru-2(dNSAID)(4)(H2O)(2)]PF6 complexes, where dNSAID = deprotonated carboxylate from the non-steroidal anti-inflammatory drugs (NSIDs), respectively: ibuprofen, Hibp (1) and aspirin, Hasp (2); ...
Ru (II)–thyminate complexes new metallodrug candidates against tumor cells
(Royal Society of Chemistry, 2019)
Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity
(Bentham Science Publishers, 2017-01)
Cancer is a group of diseases involving abnormal cell growth. The cells grow uncontrollably with the potential to invade and spread to other parts of the body. This disease is one of the principal death causes in the world, ...
Functionalized nanoparticles as adjuvant to increase the cytotoxicity of metallodrugs toward tumor cells
(2019-01-07)
Functionalized MCM-41 is a class of new nanoporous biomaterials extensively studied as drug carriers of a diversity of therapeutic agents due to its suitable properties. In the present study, two oxindolimine complexes ...
Vanadium and cancer treatment: In vitro evidences
(Nova Science Publishers, 2019)
Cancer is a group of diseases involving abnormal cell growth. in which the cells grow uncontrollably with the potential of invade and spread to other parts of the body. This group of diseases is one of the main death causes ...
Ru-90@bio-MOF-1: A ruthenium(II) metallodrug occluded in porous Zn-based MOF as a strategy to develop anticancer agents
(2021-05-01)
One of the major challenges in the field of biomedicine is to use biocompatible carriers to achieve efficient drug delivery in the body. Most of the existing carriers have shown poor loading and rapid drug release. In this ...